BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its shares of common stock have been approved for to the NASDAQ Capital Market, and will commence trading on the NASDAQ Capital Market when trading begins on September 30, 2014. previous announcement that from September 16, 2014 until October 14, 2014 their shares would be quoted as "BCLID" in order to designate the recent one for fifteen reverse split of Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases.
http://ift.tt/1pnQm4y
http://ift.tt/1pnQm4y
No comments:
Post a Comment